Author: Bioventures Team

News

We’re Hiring: Research Program Manager  

Do you have a passion for advancing scientific innovation through program leadership? BioVentures is looking for a Research Program Manager to help us build the future of biomedical entrepreneurship and translational research in Arkansas.  This role is perfect for someone who thrives at the intersection of science, strategy, and operations.  What you’ll do:  • Lead and manage multi-year grants that support innovation, entrepreneurship, and commercialization  • Coordinate educational programs that help researchers turn discoveries into real-world solutions  • Collaborate with faculty, industry partners, funders, and leadership to move complex projects forward  • Oversee budgets, reporting, compliance, and timelines across multiple initiatives  Why join us?  • Be part of a mission-driven team supporting health innovation at UAMS and beyond  • Help grow Arkansas’s biomedical innovation ecosystem  • Gain exposure to federal funding agencies, and state and national commercialization networks  • Work in a collaborative environment that values initiative, creativity, and impact  About you:  • You have experience in biomedical research, grant management, or academic programs  • You’re highly organized, proactive, and an excellent communicator  • You bring a strong understanding of higher ed or biomedical research environments  • Familiarity with entrepreneurship, tech transfer, or commercialization is a plus, but curiosity and willingness to learn are just as important  Apply now: Research Program Manager – UAMS / BioVentures  Know someone who’d be great in this role? Please share! 

Read More »
News

Dr. Megan Reed Awarded the Susan Riley Keyes Memorial Fellowship 

We’re proud to share that our Senior Licensing Associate, Megan Reed PhD, MBA has been selected as a 2025 recipient of the Susan Riley Keyes Memorial Fellowship from the AUTM Foundation. This highly competitive fellowship supports early-career technology transfer professionals through:  • Mentorship from seasoned leaders in the field  • Specialized training in invention evaluation, patenting, licensing, and commercialization  • Full access to AUTM educational resources, including the Technology Transfer Practice Manual and webinar library  • Registration, travel, and lodging for the AUTM Essentials Course, AUTM Annual Meeting, and regional meetings  • Networking opportunities with a national cohort of fellows and industry experts  Only three fellows were selected from a pool of  50 applicants, and Megan is one of them. This fellowship will deepen her expertise and broaden her professional network, further strengthening BioVentures’ ability to support UAMS innovators and drive the commercialization of life-changing biomedical technologies.  Join us in congratulating Megan on LinkedIn!

Read More »
News

A New Approach to Overcome Immunotherapy Resistance 

Newly granted patent: U.S. Patent No. 12,268,674 B2, “Mi-2β Inhibitor as an Immunotherapy Agent”  What’s the problem?  Immune checkpoint therapies, such as anti-PD-1 antibodies (e.g. Keytruda, Opdivo), have transformed cancer treatment. Yet many patients either don’t respond at all or eventually develop resistance. This limits their long-term effectiveness, leaving a major gap in oncology care.  What does this technology do?  This patent covers novel small-molecule inhibitors that block the ATPase pocket of Mi-2β (CHD4), a chromatin remodeling protein identified as a key driver of PD-1 resistance.  One lead compound, Z36-MP5, restores responsiveness to PD-1 therapy by:  By directly targeting tumor-intrinsic resistance mechanisms, Mi-2β inhibitors open the door to a first-in-class therapeutic strategy to make immunotherapy work for more patients. 

Read More »
Events

BioVentures to Participate in the TRI Research Expo 2025 

BioVentures will be present at the Translational Research Institute (TRI) Research Expo 2025, taking place Wednesday, September 10, from 4:00 to 6:00 p.m. CDT at the Reynolds Institute on Aging, First Floor.  The Expo brings together more than 50 research services across UAMS, providing investigators with the opportunity to explore resources, build connections, and learn about available support for advancing their work. Visitors can stop by the BioVentures table to discuss invention disclosures, licensing, commercialization pathways, and opportunities to bring biomedical innovations to market.  Don’t miss the chance to connect with colleagues, enjoy refreshments, and learn how BioVentures can support your research journey.  👉 Register here

Read More »
Events

HSE Grand Rounds to Feature Dr. Stefanie Kennon-McGill

Stefanie Kennon-McGill, Ph.D., Senior Program Manager at BioVentures LLC, will be the featured speaker at 2 p.m. Wednesday, August 27, for the Health Sciences Entrepreneurship Grand Rounds. The topic will be “Leveraging Commercialization to Further Your Impact.” Join us at the Winthrop P. Rockefeller Cancer Institute, 10th Floor, Betsy Blass Conference Room.  The UAMS community and public are welcome to attend.

Read More »
Blog

From Disclosure to Market: How the BioVentures Process Works 

Curious how an idea becomes a protected invention at UAMS?  At BioVentures, we guide innovators through every step, from disclosure to patent decisions and market strategy. Here’s how the process works, what to expect, and how we support you along the way. 1) Submit Your Invention Disclosure  The first step is fully and adequately disclosing your invention to BioVentures by submitting an invention disclosure. Even if you’ve already reached out to schedule a meeting, we require a disclosure to initiate the process. It allows us to review the technology in advance, and gather essential information on compliance, funding, and inventorship.  We’ve recently adopted a new AI-powered disclosure platform to simplify the process. You can upload relevant documents—papers, figures, posters, presentations—and the system will generate a draft disclosure for you to review and edit before submission:  👉 Submit your disclosure  The form captures a complete overview of your invention, its potential applications, and any existing data or prototypes. Once submitted, BioVentures typically reviews the disclosure within 1–2 weeks before scheduling a meeting with you.  Typical timing: BioVentures review in 1–2 weeks.  2) Meeting with the Technology Manager  We meet with the inventor to clarify the technology, confirm federal compliance needs, capture inventor and funding information, and discuss long‑term goals and commercialization paths.  Typical timing: Scheduled within 1–2 weeks after disclosure review.  3) P&CC Decision (Patent & Copyright Committee)  The inventor presents at the P&CC. This committee reviews the presented technology and makes a determination on how the technology should be protected. Outcomes can include:  Typical timing: P&CC is usually scheduled 1–2 months after acceptance of the disclosure.  4) Protection Strategy Based on P&CC Outcome  The legal protection route follows the P&CC decision. If a provisional patent filing is recommended, we move quickly to secure a priority date and a 12‑month window to strengthen data and assess market potential. This is because in the United States is a first to file country which means that the right to a patent generally belongs to whichever inventor files an application with the USPTO first, not to whoever first conceives the idea. As such, protecting your invention in a timely manner is important to us.   Typical timing: Provisional filing is typically completed within a few weeks of the P&CC meeting.  5) Marketing and Commercial Pathways  If the inventor agrees, we begin targeted outreach. Options include:  Why Early Disclosure Matters  Submitting your invention disclosure early is essential. It helps preserve your patent rights before any public disclosure or publication, ensuring your ability to pursue protection. Early disclosure also allows BioVentures to align your IP strategy with funding sources and compliance requirements, and accelerates our ability to evaluate the market potential and identify relevant partners.  This overview is for general information and does not constitute legal advice. Specific strategies and timelines may vary by technology.  Have an invention to disclose? Submit your disclosure now!

Read More »
Blog

BioVentures Supports UAMS M1 Students in PCAR Summer Program

BioVentures supported University of Arkansas for Medical Sciences (UAMS) first-year medical students this summer through the Partnership in Cancer Research (PCAR) program. Over eight weeks, participants worked in multidisciplinary teams to address real-world challenges in cancer prevention, diagnosis, treatment, or survivorship. The program culminated in entrepreneurial pitch presentations to a panel of judges. Three BioVentures team members served as mentors, advising students on refining problem statements, assessing market opportunities, and developing business models. Another team member participated as a judge, providing feedback from a commercialization perspective. The collaboration aimed to foster entrepreneurial thinking, highlight the role of innovation in cancer care, and encourage future clinician-innovators at UAMS. This initiative reflects BioVentures’ ongoing commitment to advancing healthcare entrepreneurship and translating research into real-world impact.

Read More »
News

A New Antibody Detects a Hidden Cancer Signal 

Newly granted patent: U.S. Patent No. 12,281,171 B2, “Periostin Antibodies and Methods of Using the Same” What’s the problem? Some cancers create a unique “signal” by adding a rare sugar modification to proteins like periostin. This tumor-specific marker could help identify and target cancer, but it’s extremely difficult to detect. Traditional tools often miss it because these sugar structures are hard for the immune system to recognize.  What does this technology do? This patent covers a new monoclonal antibody, C9, that targets the sugar marker not the whole protein. Using samples from ovarian cancer patients, inventors at UAMS identified an antibody that binds precisely to this cancer-specific structure. In mouse models, this C9 antibody successfully located and attached to tumors, showing strong potential for cancer imaging and targeted treatment. 

Read More »
Blog

Building Translational Skills: Inside the 2025 BioVentures Internship 

BioVentures’ 2025 interns modernized core data systems and explored how UAMS innovations reach the market, bridging science and business.  BioVentures is wrapping up its 2025 Internship Program on August 1, with two standout students who have brought fresh energy and dedication to the office: Carter Horton and Nyera Ali.   Carter, a sophomore in Biomedical Engineering and National Merit Scholar at the University of Arkansas, described his experience by saying: “This internship has shown me how science and business connect to improve lives. It’s exciting to see it firsthand.”  Nyera, a rising senior at Pulaski Academy, is a Model United Nations standout and one of only seven students from Arkansas selected to compete at the prestigious Regeneron International Science and Engineering Fair for her genome-editing research. Participating through the Summer Research Institute (SRI), she has been working with Dr. Mitch McGill on research involving acetaminophen-induced liver injury.   Throughout the summer, both interns have played a role in transferring and organizing key data into a new system, a project that will serve as the foundation for future operations at BioVentures. In doing so, they’ve gained direct exposure to the process of technology transfer and learned how discoveries at UAMS move from the lab into the real world through commercialization.  We’re grateful to have had them with us this summer and look forward to seeing where their paths lead next.  Interested in interning with BioVentures in 2026? Contact tforcum@uams.edu. 

Read More »
Blog

Bringing Discoveries to Life: Technology Transfer at UAMS 

Every breakthrough at the University of Arkansas for Medical Sciences (UAMS) starts the same way: a question, an experiment, a spark of insight. Yet fewer than 10% of academic discoveries are ever licensed, and even fewer become commercial products, because the gap between lab work and real-world adoption is wider than it looks.  That’s where technology transfer, and BioVentures, steps in.  What Exactly Is Technology Transfer?  In simple terms, technology transfer (or “tech transfer”) is the structured hand-off of intellectual property (IP), data and know-how from a research institution to an outside partner that can turn it into a product, service or startup. At UAMS, tech transfer means:  Why It Accelerates the Path to Market  Great research doesn’t always lead to real-world impact, at least not on its own. In fact, many promising discoveries stall in the gap between publication and commercialization. Without structured support, this “valley of death” can prevent life-changing technologies from ever reaching patients, products, or public benefit.  That’s where technology transfer makes the difference. By removing common roadblocks, it turns isolated breakthroughs into scalable innovations.  Here are three key barriers in traditional academic research, and how technology transfer helps overcome them:  1. No Clear Ownership = No Investment  Most companies won’t touch an invention unless it’s clearly protected. If the intellectual property (IP) isn’t patented or officially disclosed, it becomes risky. No one wants to invest in something they can’t legally control or defend.  Tech transfer solution: BioVentures helps UAMS researchers secure IP rights through provisional or utility patents. This provides legal certainty for potential partners and investors, paving the way for serious interest and funding.  2. Funding Gaps After Publication  Once a discovery is published, grant funding often slows down and there’s rarely institutional support to turn research into a product. That leaves many innovations in limbo.  Tech transfer solution: Through licensing agreements, BioVentures creates new revenue streams. Royalties and milestone payments help fund continued development, validation, and even new lines of research.  3. Limited Access to Commercial Partners  Researchers often lack direct access to industry players who could bring their technologies to market. Cold outreach rarely works, and there’s no playbook for navigating the startup or med-tech space alone.  Tech transfer solution: BioVentures maintains an active network of industry contacts, including venture firms, pharma companies, and medical device manufacturers. We make the introductions—and manage the conversations—so your science gets in front of the right people.  What’s in It for UAMS Inventors?  Your First Step: The Invention Disclosure  Submitting a disclosure takes ≈10 minutes and should be done before you publish or present.  Ready to Make an Impact?  Stay on top of funding calls, licensing success stories and practical IP tips. Subscribe to the BioVentures Newsletter and turn your research into real-world change.  Subscribe Now 

Read More »